| Autor: |
Alain Townsend, Pramila Rijal, Julie Xiao, Tiong Kit Tan, Kuan-Ying Huang, Lisa Schimanski, Jiandong Huo, Nimesh Gupta, Rolle Rahikainen, Philippa Matthews, Derrick Crook, Sarah Hoosdally, Teresa Street, Justine Rudkin, Nicole Stoesser, Fredrik Karpe, Matthew Neville, Rutger Ploeg, Marta Oliveira, David Roberts, Abigail Lamikanra, Hoi Tsang, Abbie Bown, Richard Vipond, Alexander Mentzer, Julian Knight, Andrew Kwok, Gavin Screaton, Juthathip Mongkolsapaya, Wanwisa Dejnirattisai, Piyasa Supasa, Paul Klenerman, Christina Dold, J Baillie, Shona Moore, Peter Openshaw, Malcolm Semple, Lance Turtle, Mark Ainsworth, Alice Allcock, Sally Beer, Sagida Bibi, Elizabeth Clutterbuck, Alexis Espinosa, Maria Mendoza, Dominique Georgiou, Teresa Lockett, Jose Martinez, Elena Perez, Veronica Sanchez, Giuseppe Scozzafava, Alberto Sobrinodiaz, Hannah Thraves, Etienne Joly |
| Rok vydání: |
2020 |
| Popis: |
Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of seroconversion in populations, detection of seroconversion after vaccination, and for seeking evidence for a level of antibody that may be protective against COVID-19 disease. Several high-performance commercial tests have been described, but these require centralised laboratory facilities that are comparatively expensive, and therefore not available universally. Red cell agglutination tests have a long history in blood typing, and general serology through linkage of reporter molecules to the red cell surface. They do not require special equipment, are read by eye, have short development times, low cost and can be applied as a Point of Care Test (POCT). We describe a red cell agglutination test for the detection of antibodies to the SARS-CoV-2 receptor binding domain (RBD). We show that the Haemagglutination Test (HAT) has a sensitivity of 90% and specificity of 99% for detection of antibodies after a PCR diagnosed infection. The HAT can be titrated, detects rising titres in the first five days of hospital admission, correlates well with a commercial test that detects antibodies to the RBD, and can be applied as a point of care test. The developing reagent is composed of a previously described nanobody to a conserved glycophorin A epitope on red cells, linked to the RBD from SARS-CoV-2. It can be lyophilised for ease of shipping. We have scaled up production of this reagent to one gram, which is sufficient for ten million tests, at a cost of ~0.27 UK pence per test well. Aliquots of this reagent are ready to be supplied to qualified groups anywhere in the world that need to detect antibodies to SARS-CoV-2, but do not have the facilities for high throughput commercial tests. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
